Cargando…

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings

BACKGROUND: To guide future need for cheap resistance tests for use in low income settings, we assessed cost-effectiveness of drug resistance testing as part of monitoring of people on first line ART - with switching from first to second line ART being conditional on NNRTI drug resistance mutations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Andrew, Cambiano, Valentina, Nakagawa, Fumiyo, Magubu, Travor, Miners, Alec, Ford, Debbie, Pillay, Deenan, De Luca, Andrea, Lundgren, Jens, Revill, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188574/ https://www.ncbi.nlm.nih.gov/pubmed/25290340 http://dx.doi.org/10.1371/journal.pone.0109148

Ejemplares similares

Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries
por: Cambiano, Valentina, et al.
Publicado: (2015)

Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring
por: von Wyl, Viktor, et al.
Publicado: (2012)

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
por: Phillips, Andrew N., et al.
Publicado: (2017)

Projected Lifetime Healthcare Costs Associated with HIV Infection
por: Nakagawa, Fumiyo, et al.
Publicado: (2015)

Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM
por: Phillips, Andrew N., et al.
Publicado: (2015)

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2018)

Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa
por: Phillips, Andrew N., et al.
Publicado: (2016)

Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic
por: Phillips, Andrew N., et al.
Publicado: (2013)

Potential Future Impact of a Partially Effective HIV Vaccine in a Southern African Setting
por: Phillips, Andrew N., et al.
Publicado: (2014)

Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa
por: Phillips, Andrew N, et al.
Publicado: (2016)

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
por: Phillips, Andrew N, et al.
Publicado: (2020)

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2017)

Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure
por: Shroufi, Amir, et al.
Publicado: (2019)

Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care
por: Revill, Paul, et al.
Publicado: (2018)

Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile
por: Phillips, Andrew N., et al.
Publicado: (2016)

Update on HIV in Western Europe
por: Nakagawa, Fumiyo, et al.
Publicado: (2014)

Preferences for HIV testing services among men who have sex with men in the UK: A discrete choice experiment
por: Miners, Alec, et al.
Publicado: (2019)

Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2019)

Correction: Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings
Publicado: (2014)

‘Dark matter’, second waves and epidemiological modelling
por: Friston, Karl, et al.
Publicado: (2020)

High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial
por: Kityo, Cissy, et al.
Publicado: (2014)

Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
por: Castro, Hannah, et al.
Publicado: (2012)

Combination antiretroviral therapy and cell–cell spread of wild-type and drug-resistant human immunodeficiency virus-1
por: Titanji, Boghuma Kabisen, et al.
Publicado: (2017)

Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models
por: Bershteyn, Anna, et al.
Publicado: (2022)

Potential Impact and Cost-Effectiveness of Condomless-Sex–Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance
por: Phillips, Andrew N, et al.
Publicado: (2019)

Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa
por: Simmons, Bryony, et al.
Publicado: (2014)

Cost‐effectiveness of routine viral load monitoring in low‐ and middle‐income countries: a systematic review
por: Barnabas, Ruanne V, et al.
Publicado: (2017)

Use of Surveillance Data on HIV Diagnoses with HIV-Related Symptoms to Estimate the Number of People Living with Undiagnosed HIV in Need of Antiretroviral Therapy
por: Lodwick, Rebecca K., et al.
Publicado: (2015)

Modelling the Potential Population Impact and Cost-Effectiveness of Self-Testing for HIV: Evaluation of Data Requirements
por: Cambiano, Valentina, et al.
Publicado: (2014)

Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch
por: Johnston, Victoria, et al.
Publicado: (2014)

Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis
por: Baggaley, Rebecca F, et al.
Publicado: (2017)

A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model
por: Nakagawa, Fumiyo, et al.
Publicado: (2016)

The Effect of Antiretroviral Treatment on Health Care Utilization in Rural South Africa: A Population-Based Cohort Study
por: Hontelez, Jan A. C., et al.
Publicado: (2016)

Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients
por: Häggblom, Amanda, et al.
Publicado: (2017)

Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
por: Pierre, Samuel, et al.
Publicado: (2021)

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
por: Schultze, Anna, et al.
Publicado: (2014)

Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2011)

Treatment Effect and Drug-Resistant Mutations in Chinese AIDS Patients Switching to Second-Line Antiretroviral Therapy
por: Zhang, Min, et al.
Publicado: (2014)

Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy
por: Huntington, Susie, et al.
Publicado: (2015)

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy
por: Huntington, Susie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bc80jo23qldo2olosovbj43o9j